The journey to end cystic fibrosis isn’t a straight line. It’s an evolving map with many paths and unique challenges. That’s why we’re pursuing several different approaches to help achieve our goal of restoring CFTR protein and function in 100 percent of people living with cystic fibrosis. Dr. Bill Skach, EVP and Chief Scientific Officer at the Foundation, discusses how genetic-based therapies such as mRNA therapy, DNA therapy or gene therapy, and gene editing, could allow normal CFTR protein to

Confused on how gene editing could be used for people living with cystic fibrosis? Watch this animation to get a better understanding of how this technology might one day be used to edit mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that causes CF. | Cystic Fibrosis Foundation